Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
AnaptysBio IncANAB-3.098.946.06-3.60-161.82%-27.92%0.00$18.26$114.2824,546$17.69

Detail of AnaptysBio Inc

 
CEO
Mr. Daniel R. Faga
Employees
117
Industry
Biotechnology
Sector
Healthcare
Market cap
$511M

Company details

AnaptysBio Inc. is a clinical-stage biotechnology company dedicated to developing innovative antibody therapies for the treatment of various diseases. Primarily focused on unmet medical needs in immuno-oncology and inflammation, AnaptysBio leverages its proprietary somatic hypermutation-based antibody discovery platform to create novel therapeutic agents. The company's pipeline includes a range of humanized monoclonal antibodies targeting specific cellular pathways to inhibit or enhance immune responses. AnaptysBio plays a pivotal role in the biopharmaceutical industry, aiming to advance the development of targeted treatments that can improve the quality of life for patients with serious medical conditions. With its commitment to research and development, the company significantly contributes to the evolving landscape of precision medicine and personalized healthcare solutions.

Revenue
Revenue (Rev)
$57.17M
AnaptysBio Inc
ANAB • XNGS • US
$17.69
-5.48 (-23.65%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$5.73
Margin profit
-289.75%
52 week low
$12.2855
52 week high
$40.330002
50-day simple moving average
$17.92
200-day simple moving average
$18.26
Percent held by insiders
4.44%
Percent held by institutions
114.42%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ANAB -23.65%
eps change
ANAB 0.00%